Press Releases

Press Releases

Summary Toggle PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020

INCLINE VILLAGE, Nev. , April 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020 , on Thursday, May 7, 2020 , after market close.

Apr 30, 2020
Summary Toggle PDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020

- 2019 Revenue Guidance Exceeded - - Monetization Process Underway - - PDL Board Approved Plan of Complete Liquidation and Plans to Seek Stockholder Approval for Dissolution of the Company - - Targeting to File a Certificate of Dissolution under Delaware Law by Year-End 2020 - - Conference Call at

Mar 11, 2020
Summary Toggle PDL BioPharma Announces Appointment of Edward A. Imbrogno as Vice President and Chief Financial Officer

INCLINE VILLAGE, Nev. , March 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the appointment of Edward A. Imbrogno as the Company's Vice President and Chief Financial Officer. Mr. Imbrogno joined PDL as Vice President of Finance in October 2018

Mar 9, 2020
Summary Toggle PDL BioPharma to Announce 2019 Fourth Quarter and Full Year Financial Results on March 11, 2020

INCLINE VILLAGE, Nev. , March 4, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its 2019 fourth quarter and full year financial results for the period ended December 31, 2019 , on Wednesday, March 11, 2020 , after market close.

Mar 4, 2020
Summary Toggle PDL BioPharma Enters into Cooperation Agreement with Engine Capital

Appoints New Independent Director Alan L. Bazaar to its Board of Directors INCLINE VILLAGE, Nev. , Feb. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with

Feb 28, 2020
Summary Toggle PDL BioPharma to Participate in the Cowen and Company 40th Annual Health Care Conference

INCLINE VILLAGE, Nev. , Feb. 25, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, will present at the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 at

Feb 25, 2020
Summary Toggle PDL BioPharma Announces Upcoming Changes to its Board of Directors

Director Elizabeth O'Farrell Named Chairperson of the Board Chairperson Dr. Harold E. Selick to Retire from Board by Year-End Director Paul Sandman to Retire at 2020 Annual Meeting Board to be Reduced to Six Directors Following 2020 Annual Meeting INCLINE VILLAGE, Nev. , Dec.

Dec 19, 2019
Summary Toggle PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million

INCLINE VILLAGE, Nev. , Dec. 16, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that its Board of Directors has authorized a $75 million increase to the $200 million common stock and convertible notes repurchase authorization that was previously

Dec 16, 2019
Summary Toggle PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024

INCLINE VILLAGE, Nev. , Dec. 13, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its

Dec 13, 2019
Summary Toggle PDL BioPharma Announces Completion of Strategic Review Process

Will Pursue Monetization of its Assets and Optimal Means of Returning Proceeds to Shareholders; Will Cease Making Additional Strategic Acquisitions and Investments Board Authorizes Repurchase Program to Acquire up to $200 Million of Outstanding PDL Stock and Convertible Notes Conference Call at

Dec 9, 2019
Summary Toggle PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®

INCLINE VILLAGE, Nev. , Dec. 3, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM) on its recent achievement of two major regulatory and clinical milestones with its lead product candidate Amphora ®

Dec 3, 2019
Summary Toggle PDL BioPharma Reaffirms Commitment To Shareholder Value Creation

Responds to Escalation of Engine Capital's Public Campaign INCLINE VILLAGE, Nev. , Nov. 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine") escalation of its public campaign

Nov 14, 2019
Summary Toggle PDL BioPharma Reports 2019 Third Quarter Financial Results

Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets Conference call at 4:30 p.m. Eastern time today INCLINE VILLAGE, Nev. , Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for

Nov 6, 2019
Summary Toggle PDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019

INCLINE VILLAGE, Nev. , Oct. 30, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the period ended September 30, 2019 , on Wednesday, November 6, 2019 , after market close.

Oct 30, 2019
Summary Toggle PDL BioPharma Responds to Letter from Engine Capital

INCLINE VILLAGE, Nev. , Oct. 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick , Ph.D., Chairman of the Board of Directors of PDL BioPharma , has sent the following letter to Engine Capital, LP .

Oct 24, 2019